TB-500 vs KPV
Both are discussed for recovery/inflammation, but neither has identified human drug-product exposure evidence sufficient to establish efficacy or safety.
| Attribute | TB-500 | KPV |
|---|---|---|
| Human evidence | FDA reports no identified human drug-product exposure for the TB-500 fragment. A 2026 rat Achilles-tendon study provides animal evidence for a material the authors call TB-500, but the inspected paper does not independently establish that it was the FDA-defined LKKTETQ fragment. A fictional/example registry record is not counted as human evidence. | FDA reports no identified human drug-product exposure to KPV by any route. Human-derived keratinocyte studies are in vitro and do not constitute clinical exposure. |
| Research focus | Wound/tissue-repair research claims | Inflammation, gut, skin and wound biology |
| Regulatory status | Not FDA-approved; FDA has reviewed TB-500-related substances in the compounding context and highlights safety/data gaps. | Not FDA-approved; FDA highlights lack of human exposure and safety data. |
| Route / formulation | TB-500 fragment evidence must remain separate from full-length thymosin beta-4 and from fictional/example registry content. | Topical, oral and injectable claims should be separated because route changes exposure and risk. |
Why these are compared
These compounds appear in the recovery / inflammatory research evidence landscape, but they are not interchangeable. TB-500 is synthetic fragment of thymosin beta-4 studied in wound/tissue-repair research claims; KPV is alpha-msh-derived tripeptide studied in inflammation, gut, skin and wound biology. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
TB-500: Identity-qualified preclinical evidence; confirmed human drug-exposure gap.
KPV: Preclinical / human-cell mechanistic; no established human drug exposure.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No head-to-head human evidence. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty. For any compound with little or no established human exposure, published human safety and efficacy data would also materially change the evidence picture.